IMF Videos Search Content For Healthcare Professional (76) Healthcare Provider (75) Care Partner (65) Patient (65) Series - Any - ASCO/EHA (31) ASH (30) Ask Dr. Durie (16) Community Workshops (3) Emerging Therapies (12) Facebook Live (6) Health Equity (4) IMWG (3) Living Well with Myeloma (3) Myeloma in a Minute (2) Myeloma Made Simple (6) Myeloma University (9) Q&A (6) Recent News and Developments (2) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (88) High-Risk Myeloma (38) High-risk Smoldering Myeloma (17) Late Relapse (4–6 Lines of Therapy) (101) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (24) Smoldering Myeloma (13) Types of Therapy Immunomodulatory drugs (IMiDs) (31) Immunotherapies (CAR T; BiTE, etc.) (97) Monoclonal antibodies (33) Proteasome inhibitors (23) Stem cell transplant (24) Steroids (20) Supportive Care (36) Year Published 2026 (18) 2025 (22) 2024 (35) 2023 (39) 2022 (4) 2021 (4) 2020 (3) 2019 (2) 2018 (1) 2017 (1) 2016 (4) 2015 (2) Trusted Voices Dr. Joseph Mikhael (35) Dr. Brian GM Durie (15) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Donna Catamero, ANP-BC, OCN, CCRC (3) Dr. María-Victoria Mateos (2) Dr. Saad Usmani (2) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse July 12, 2024 ASCO/EHA Class comparison of BCMA-directed therapies in relapsed multiple myeloma June 24, 2024 ASCO/EHA MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma June 21, 2024 ASCO/EHA Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed Refractory Multiple Myeloma June 21, 2024 ASCO/EHA LINKER-MM1: Linvoseltamab for RR Multiple Myeloma Deep, Durable Responses at 14-Month Follow-Up June 20, 2024 ASCO/EHA Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study June 19, 2024 ASCO/EHA DREAMM-8 Study: Belantamab mafodotin plus pomalidomide and dexamethasone shows improved outcomes in relapsed/refractory multiple myeloma June 14, 2024 ASCO/EHA Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma June 6, 2024 ASCO/EHA Myeloma Made Simple: Bispecific Antibody Targets Made Simple | Myeloma Targeting with Bispecifics June 6, 2024 Myeloma Made Simple Myeloma Made Simple: Bispecific Antibodies Made Simple | Bispecific Antibodies for Myeloma Treatment May 29, 2024 Myeloma Made Simple Myeloma Made Simple: Xpovio (Selinexor) Made Simple | Selinexor for Multiple Myeloma Treatment May 15, 2024 Myeloma Made Simple What should be done if a patient relapses while in a clinical trial? April 19, 2024 Ask Dr. Durie Load More
